Beta Pharma, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Beta Pharma, Inc.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2015.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
BeiGene CEO John Oyler On Investing In Biotech In China: An Interview With PharmAsia News (Part 2 of 2)
BeiGene CEO John Oyler discusses what is missing in China’s venture capital environment if it truly wants to foster innovation. Based in Beijing, BeiGene’s lead product entered the clinic in 2013.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Beta Chemicals, Inc.
- Beta Pharma Canada Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.